Morgan Stanley
APTO

Morgan Stanley’s Aptose Biosciences, Inc. APTO Stock Holding History

Morgan Stanley’s Portfolio APTO Stock Details APTO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-101
Closed -$318 – 8397
2025
Q1 		$318 Sell
101
-82
-45% -$399 ﹤0.01% 7424
2024
Q4 		$1.24K Sell
183
-862
-82% -$7.86K ﹤0.01% 7247
2024
Q3 		$12.9K Buy
1,045
+33
+3% +$503 ﹤0.01% 6640
2024
Q2 		$23K Sell
1,012
-118
-10% -$4K ﹤0.01% 6412
2024
Q1 		$56.3K Sell
1,130
-4,834
-81% -$277K ﹤0.01% 6171
2023
Q4 		$454K Buy
5,964
+4,401
+282% +$341K ﹤0.01% 5654
2023
Q3 		$131K Sell
1,563
-6
-0.4% -$707 ﹤0.01% 5756
2023
Q2 		$218K Buy
1,569
+6
+0.4% +$1.24K ﹤0.01% 5615
2023
Q1 		$450K Buy
1,563
+17
+1% +$4.94K ﹤0.01% 5318
2022
Q4 		$403K Sell
1,546
-171
-10% -$45.9K ﹤0.01% 5345
2022
Q3 		$460K Sell
1,717
-369
-18% -$127K ﹤0.01% 5310
2022
Q2 		$697K Buy
2,086
+179
+9% +$85.6K ﹤0.01% 5245
2022
Q1 		$1.17M Sell
1,907
-1,020
-35% -$564K ﹤0.01% 4883
2021
Q4 		$1.78M Sell
2,927
-378
-11% -$355K ﹤0.01% 4671
2021
Q3 		$3.24M Buy
3,305
+1,978
+149% +$2.47M ﹤0.01% 4150
2021
Q2 		$1.98M Buy
1,327
+200
+18% +$436K ﹤0.01% 4645
2021
Q1 		$3.03M Buy
1,127
+73
+7% +$145K ﹤0.01% 3914
2020
Q4 		$2.08M Buy
1,054
+18
+2% +$42.3K ﹤0.01% 4124
2020
Q3 		$2.8M Buy
1,036
+287
+38% +$716K ﹤0.01% 3335
2020
Q2 		$2.13M Sell
749
-155
-17% -$500K ﹤0.01% 3536
2020
Q1 		$2.42M Sell
904
-93
-9% -$277K ﹤0.01% 3199
2019
Q4 		$2.54M Buy
997
+173
+21% +$225K ﹤0.01% 3847
2019
Q3 		$773K Buy
824
+123
+18% +$140K ﹤0.01% 4442
2019
Q2 		$824K Buy
701
+120
+21% +$110K ﹤0.01% 4327
2019
Q1 		$526K Sell
581
-255
-31% -$231K ﹤0.01% 4517
2018
Q4 		$720K Sell
836
-113
-12% -$111K ﹤0.01% 4534
2018
Q3 		$1.11M Buy
949
+146
+18% +$196K ﹤0.01% 4453
2018
Q2 		$1.42M Buy
803
+405
+102% +$646K ﹤0.01% 4375
2018
Q1 		$566K Buy
398
+267
+204% +$357K ﹤0.01% 4936
2017
Q4 		$132K Buy
131
+50
+62% +$38.6K ﹤0.01% 5555
2017
Q3 		$54K Buy
81
+69
+575% +$46.3K ﹤0.01% 5762
2017
Q2 		$7K Hold
12
– – ﹤0.01% 6309
2017
Q1 		$6K Hold
12
– – ﹤0.01% 6332
2016
Q4 		$8K Sell
12
-8
-40% -$4.98K ﹤0.01% 6208
2016
Q3 		$20K Buy
20
+4
+25% +$4.16K ﹤0.01% 5917
2016
Q2 		$18K Buy
16
+14
+700% +$16.5K ﹤0.01% 5890
2016
Q1 		$2K Buy
2
+1
+100% +$1.19K ﹤0.01% 6415
2015
Q4 		$2K Hold
1
– – ﹤0.01% 6519
2015
Q3 		$3K Hold
1
– – ﹤0.01% 6460
2015
Q2 		$3K Hold
1
– – ﹤0.01% 6483
2015
Q1 		$3K Buy
+1
New +$2.42K ﹤0.01% 6406
2014
Q4 		– Hold
0
– – – 6705

Other funds holding APTO

DS
DRW Securities Chicago, Illinois $7.21B AUM 20.54% 1-Year Est. Return
GG
Gleason Group Prospect, Kentucky $1.15B AUM 21.11% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $33.7B AUM 35.49% 1-Year Est. Return
CSC
Caldwell Sutter Capital Sausalito, California $246M AUM 23.62% 1-Year Est. Return

Morgan Stanley's APTO Position: Q2 2025 in Review

Morgan Stanley sold out of Aptose Biosciences, Inc. (APTO) in Q2 2025, closing a stake of 101 shares — an estimated $318 sold.

Morgan Stanley first reported a position in APTO in Q1 2015 and held it in 41 quarters. The position peaked at $3.24M in Q3 2021. 4 funds tracked by Wall St. Rank hold APTO as of Q2 2025.

  • Morgan Stanley reported no remaining Aptose Biosciences, Inc. position as of Q2 2025 after selling out during the quarter.
  • Morgan Stanley sold 101 Aptose Biosciences, Inc. shares in Q2 2025, an estimated $318.
  • Morgan Stanley first reported a position in Aptose Biosciences, Inc. in Q1 2015 and held it in 41 quarters.
  • Morgan Stanley's Aptose Biosciences, Inc. position peaked at $3.24M in Q3 2021.
  • 4 funds tracked by Wall St. Rank held Aptose Biosciences, Inc. as of Q2 2025.

Based on Morgan Stanley's 13F filing for Q2 2025, filed 15 Aug 2025.